Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2151 DDI with Montelukast in Healthy Men
NCT02321748Phase 1Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Amenamevir in herpes zoster (HZ) (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Peak Plasma Concentration of Montelukast at 72 hours, Time of Peak Concentration of Montelukast at 72 hours and 4 more. Started Dec 2014; status: completed.
02
Drugs
Amenamevir
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT02321748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321748.